|
1
|
Nelson WG, De Marzo AM and Isaacs WB:
Prostate cancer. N Engl J Med. 349:366–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sabbatini P, Larson SM, Kremer A, Zhang
ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, et al:
Prognostic significance of extent of disease in bone in patients
with androgen-independent prostate cancer. J Clin Oncol.
17:948–957. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khew-Goodall Y and Goodall GJ:
Myc-modulated miR-9 makes more metastases. Nat cell Biol.
12:209–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hao GJ, Ding YH, Wen H, Li XF, Zhang W, Su
HY, Liu DM and Xie NL: Attenuation of deregulated miR-369-3p
expression sensitizes non-small cell lung cancer cells to cisplatin
via modulation of the nucleotide sugar transporter SLC35F5. Biochem
Biophys Res Commun. 488:501–508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y,
Liang Y, Cao L, Li X, Li R, et al: Maintenance of cancer stemness
by miR-196b-5p contributes to chemoresistance of colorectal cancer
cells via activating STAT3 signaling pathway. Oncotarget.
8:49807–49823. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao G, Li Y and Wang T: Potentiation of
docetaxel sensitivity by miR-638 via regulation of STARD10 pathway
in human breast cancer cells. Biochem Biophys Res Commun.
487:255–261. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu
J, Wu G, Li J and Jiang L: Upregulation of miR-572
transcriptionally suppresses SOCS1 and p21 and contributes to human
ovarian cancer progression. Oncotarget. 6:15180–15193.
2015.PubMed/NCBI
|
|
9
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-kappaB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Z, Liu Z, Zhang Y, Li Y, Liu B and
Zhang K: miR-24 represses metastasis of human osteosarcoma cells by
targeting Ack1 via AKT/MMPs pathway. Biochem Biophys Res Commun.
486:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F,
Chen WY and Liu YN: Transforming growth factor-beta promotes
prostate bone metastasis through induction of microRNA-96 and
activation of the mTOR pathway. Oncogene. 34:4767–4776. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR145. Int J Oncol. 42:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang M, Ren D, Guo W, Huang S, Wang Z, Li
Q, Du H, Song L and Peng X: N-cadherin promotes
epithelial-mesenchymal transition and cancer stem cell-like traits
via ErbB signaling in prostate cancer cells. Int J Oncol.
48:595–606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin
C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key
regulator of tumorigenesis and metastasis and a novel serum marker
in breast cancer. Breast cancer Res. 19:152017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Zhang L, Lin B, Chai X, Li R,
Liao Y, Deng X, Liu Q, Yang W, Cai Y, et al: Phospholipid
phosphatase 4 promotes proliferation and tumorigenesis, and
activates Ca2+-permeable cationic channel in lung
carcinoma cells. Mol Cancer. 16:1472017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Liu F, Lin B, Luo H, Liu M, Wu J, Li
C, Li R, Zhang X, Zhou K, et al: miR150 inhibits proliferation and
tumorigenicity via retarding G1/S phase transition in
nasopharyngeal carcinoma. Int J Oncol. 2017.
|
|
20
|
Wang M, Ren D, Guo W, Wang Z, Huang S, Du
H, Song L and Peng X: Loss of miR-100 enhances migration, invasion,
epithelial-mesenchymal transition and stemness properties in
prostate cancer cells through targeting Argonaute 2. Int J Oncol.
45:362–372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheadle C, Vawter MP, Freed WJ and Becker
KG: Analysis of microarray data using Z score transformation. J Mol
Diagn. 5:73–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
23
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai Y, Ren D, Yang Q, Cui Y, Guo W, Lai Y,
Du H, Lin C, Li J, Song L, et al: The TGF-β signalling negative
regulator PICK1 represses prostate cancer metastasis to bone. Br J
Cancer. 117:685–694. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu M, Kuang Y, Wang M, Han X and Yang Q: A
microRNA expression signature as a predictor of survival for colon
adenocarcinoma. Neoplasma. 64:56–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma C, Xu B, Husaiyin S, Wang L,
Wusainahong K, Ma J, Zhu K and Niyazi M: MicroRNA-505 predicts
prognosis and acts as tumor inhibitor in cervical carcinoma with
inverse association with FZD4. Biosmed Pharmacother. 92:586–594.
2017. View Article : Google Scholar
|
|
27
|
Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ,
Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, et al: A serum microRNA
classifier for early detection of hepatocellular carcinoma: A
multicentre, retrospective, longitudinal biomarker identification
study with a nested case-control study. Lancet Oncol. 16:804–815.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fournier PG, Juarez P, Jiang G, Clines GA,
Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, et al:
The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer
metastases to bone. Cancer Cell. 27:809–821. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
No authors listed. TGF β induces a
pro-bone metastasis program in prostate cancer. Cancer Discov.
5(OF23)2015.
|
|
30
|
Yin JJ, Selander K, Chirgwin JM, Dallas M,
Grubbs BG, Wieser R, Massague J, Mundy GR and Guise TA: TGF-beta
signaling blockade inhibits PTHrP secretion by breast cancer cells
and bone metastases development. J Clin Invest. 103:197–206. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang Y, Siegel PM, Shu W, Drobnjak M,
Kakonen SM, Cordon-Cardo C, Guise TA and Massague J: A multigenic
program mediating breast cancer metastasis to bone. Cancer Cell.
3:537–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sethi N, Dai X, Winter CG and Kang Y:
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast
cancer by engaging Notch signaling in bone cells. Cancer Cell.
19:192–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Javelaud D, Mohammad KS, McKenna CR,
Fournier P, Luciani F, Niewolna M, Andre J, Delmas V, Larue L,
Guise TA, et al: Stable overexpression of Smad7 in human melanoma
cells impairs bone metastasis. Cancer Res. 67:2317–2324. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
35
|
Haflidadottir BS, Larne O, Martin M,
Persson M, Edsjo A, Bjartell A and Ceder Y: Upregulation of miR-96
enhances cellular proliferation of prostate cancer cells through
FOXO1. PLoS One. 8:e724002013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen S, Sun KX, Liu BL, Zong ZH and Zhao
Y: MicroRNA-505 functions as a tumor suppressor in endometrial
cancer by targeting TGF-alpha. Mol Cancer. 15:112016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Skinner HD, Lee JH, Bhutani MS, Weston B,
Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, et
al: A validated miRNA profile predicts response to therapy in
esophageal adenocarcinoma. Cancer. 120:3635–3641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ramachandran SS, Muiwo P, Ahmad HM, Pandey
RM, Singh S, Bakhshi S, Kumar L, Bhattacharya A and Gupta YK:
miR-505-5p and miR-193b-3p: Potential biomarkers of imatinib
response in patients with chronic myeloid leukemia. Leuk Lymphoma.
58:1981–1984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Molina-Pinelo S, Carnero A, Rivera F,
Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor
MD, Chaves M, et al: MiR-107 and miR-99a-3p predict chemotherapy
response in patients with advanced colorectal cancer. BMC Cancer.
14:6562014. View Article : Google Scholar : PubMed/NCBI
|
